Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness (PALACE)

This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

38

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Alabama
      • Birmingham, Alabama, Förenta staterna, 35222
    • California
      • Los Angeles, California, Förenta staterna, 90035
        • University of California, Los Angeles CARE Center (Site ID: 601)
        • Kontakt:
      • San Diego, California, Förenta staterna, 92103
        • UCSD Antiviral Research Center (Site ID: 701)
        • Kontakt:
      • San Francisco, California, Förenta staterna, 94110
        • University of California, San Francisco (Site ID: 801)
        • Kontakt:
      • Torrance, California, Förenta staterna, 90502-2052
        • Harbor University of California Los Angeles Center (Site ID: 603)
        • Kontakt:
    • Colorado
      • Aurora, Colorado, Förenta staterna, 80045
    • District of Columbia
      • Washington D.C., District of Columbia, Förenta staterna, 20032
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60611
        • Northwestern University (Site ID: 2701)
        • Kontakt:
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21287
        • Johns Hopkins University (Site ID: 201)
        • Kontakt:
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02114
        • Massachusetts General Hospital (Site ID: 101)
        • Kontakt:
      • Boston, Massachusetts, Förenta staterna, 02115
        • Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)
        • Kontakt:
    • New Jersey
      • Newark, New Jersey, Förenta staterna, 07103
        • New Jersey Medical School Clinical Research Center (Site ID: 31786)
        • Kontakt:
    • New York
      • New York, New York, Förenta staterna, 10010
        • Weill Cornell Chelsea (Site ID: 7804)
        • Kontakt:
      • New York, New York, Förenta staterna, 10010
        • Weill Cornell Uptown (Site ID: 7803)
        • Kontakt:
      • New York, New York, Förenta staterna, 10032
        • Columbia Physicians & Surgeons (P&S) (Site ID: 30329)
        • Kontakt:
    • North Carolina
      • Chapel Hill, North Carolina, Förenta staterna, 27599-7215
        • Chapel Hill (Site ID: 3201)
        • Kontakt:
      • Greensboro, North Carolina, Förenta staterna, 27401-1020
    • Ohio
      • Cincinnati, Ohio, Förenta staterna, 45267-0405
        • Cincinnati Clinical Research Site (Site ID: 2401)
        • Kontakt:
      • Cleveland, Ohio, Förenta staterna, 44106
      • Columbus, Ohio, Förenta staterna, 43210
        • Ohio State University (Site ID: 2301)
        • Kontakt:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Förenta staterna, 15213
        • University of Pittsburgh (Site ID: 1001)
        • Kontakt:
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37204
        • Vanderbilt Therapeutics (VT) (Site ID: 3652)
        • Kontakt:
    • Texas
      • Houston, Texas, Förenta staterna, 77030
        • Houston Advancing Research Team (Site ID: 31473)
        • Kontakt:
    • Washington
      • Seattle, Washington, Förenta staterna, 98104
        • University of Washington Positive Research (Site ID: 1401)
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Documented HIV-1 infection

  • Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use

  • HIV-1 RNA >1000 copies/mL within 60 days prior to study entry

  • Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence

  • At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance

  • Adequate laboratory parameters within 60 days prior to study entry:

    • Absolute neutrophil count >600/mm3
    • Hemoglobin ≥7.0 g/dL
    • Platelet count >50,000/μL
    • AST and ALT ≤3 × upper limit of normal
    • Estimated glomerular filtration rate >15 mL/min/1.73 m²
  • For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry

  • Ability and willingness to provide informed consent

  • Connected to a medical clinic with access to HIV care and antiretroviral therapy

Exclusion Criteria:

  • Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
  • Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
  • Child-Pugh Class C cirrhosis
  • No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
  • Prior use of lenacapavir
  • Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
  • Serious medical or psychiatric condition
  • Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
  • Current pregnancy or breastfeeding
  • Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Long-Acting Lenacapavir Plus Long-Acting Cabotegravir

Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation.

Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses.

Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment.

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Proportion of participants achieving and maintaining viral suppression (no confirmed virologic failure) while receiving long-acting lenacapavir plus cabotegravir
Tidsram: Baseline through Week 48
Baseline through Week 48

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsram: Week 48
Week 48
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsram: Week 48
Week 48
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsram: Week 48
Week 48
Proportion of participants with Grade 3 or higher adverse events related to long-acting lenacapavir plus cabotegravir
Tidsram: Baseline through Week 96
Baseline through Week 96
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir due to adverse events or intolerance
Tidsram: Baseline through Week 96
Baseline through Week 96
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure on long-acting lenacapavir plus cabotegravir
Tidsram: Baseline through Week 96
Baseline through Week 96
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsram: Week 96
Week 96
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsram: Week 96
Week 96
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsram: Week 96
Week 96
Percentage of on-time long-acting injections
Tidsram: Through Week 48 and through Week 96
Through Week 48 and through Week 96
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir
Tidsram: Baseline through Week 48 and through Week 96
Baseline through Week 48 and through Week 96
Plasma trough concentrations of lenacapavir and cabotegravir
Tidsram: Through Week 48 and through Week 96
Through Week 48 and through Week 96
Change in CD4 cell count from baseline
Tidsram: Week 48 and Week 96
Week 48 and Week 96
Participant-reported treatment satisfaction
Tidsram: Week 48 and Week 96

HIV Treatment Satisfaction Questionnaire assesses participant satisfaction with the long-acting treatment.

Week 48 and Week 96
Change in quality-of-life scores from baseline
Tidsram: Week 48 and Week 96

Quality of life will be assessed using the Veterans Rand 12-item Health Survey (VR-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life.

Week 48 and Week 96
Change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline
Tidsram: Week 48 and Week 96

Symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.

Week 48 and Week 96
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure among participants not requiring oral bridge therapy
Tidsram: Baseline through Week 48
Baseline through Week 48
Proportion of participants without oral bridge therapy with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsram: Week 48
Week 48
Proportion of participants without oral bridge therapy with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsram: Week 48
Week 48
Proportion of participants without oral bridge therapy with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsram: Week 48
Week 48

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 februari 2028

Primärt slutförande (Beräknad)

31 augusti 2029

Avslutad studie (Beräknad)

26 oktober 2030

Studieregistreringsdatum

Först inskickad

10 november 2026

Först inskickad som uppfyllde QC-kriterierna

10 november 2026

Första postat (Faktisk)

16 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • A5431
  • 39159 (Annan identifierare: DAIDS-ES ID)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Individual participant data that underlie results in the publication after deidentification

Tidsram för IPD-delning

Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH

Kriterier för IPD Sharing Access

With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.

For what types of analyses? To achieve aims in the proposal approved by the ACTG.

By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera